Experimental cell therapy aims to tame reckless immune system in brain diseases
NCT ID NCT07275736
Summary
This early-stage study is testing the safety and initial effectiveness of an experimental cell therapy called CNCT19. It is for adults with severe autoimmune diseases affecting the nervous system, like multiple sclerosis or myasthenia gravis, where standard treatments have failed. The therapy involves collecting and modifying a patient's own immune cells to potentially better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.